Arcus Biosciences

Arcus Biosciences announced that quemliclustat, an investigational small-molecule CD73 inhibitor, received FDA orphan drug designation for treating pancreatic cancer.

Arcus Biosciences reported a 46% confirmed overall response rate for the casdatifan plus cabozantinib combination in patients with clear cell renal cell carcinoma who had progressed on prior immunotherapy.

Arcus Biosciences' casdatifan demonstrates superior efficacy profile compared to Merck's Welireg in Phase I/Ib kidney cancer trial, showcasing potential advancement in HIF-2α inhibition.

Arcus Biosciences will showcase safety and efficacy data from the ARC-20 study evaluating casdatifan in previously treated kidney cancer patients at the 2025 ASCO GU Symposium.

Roche's anti-TIGIT drug, tiragolumab, failed to demonstrate a life-extending benefit in a Phase 3 trial for non-small cell lung cancer, raising concerns about the TIGIT inhibitor class.

• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders. • Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes. • Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.

The combination of domvanalimab and zimberelimab demonstrated a statistically significant improvement in overall survival (OS) compared to zimberelimab alone in advanced NSCLC patients.

Casdatifan, a HIF-2α inhibitor, demonstrated a 34% objective response rate in heavily pretreated patients with metastatic clear cell renal cell carcinoma (ccRCC).

Arcus Biosciences and AstraZeneca are collaborating to evaluate casdatifan, a HIF-2a inhibitor, with volrustomig, a PD-1/CTLA-4 bispecific antibody, for ccRCC treatment.

• Gilead Sciences has executed over $27 billion worth of strategic oncology deals in 2020, marking its most aggressive push yet to establish leadership in cancer treatment. • Under new leadership, including CEO Daniel O'Day and CFO Andrew Dickinson, Gilead has acquired Immunomedics for $21 billion and made significant investments in multiple biotech companies focused on immuno-oncology. • The company aims to balance its traditional antiviral portfolio with a strong oncology presence, highlighted by the acquisition of Trodelvy, while maintaining approximately $11 billion for future strategic investments.